Surgical Science Sweden AB publ SUSRF 2026 Q2财报电话会

发布时间：2026-08-19 一、AI总结内容 一、核心要点 1. Surgcial Science 2026年第二季度实现强劲业绩，营收255百万瑞典克朗，同比增长22%（本地货币增长25%）；调整后EBIT达38百万瑞典克朗，占比15%，符合目标。 2. 专利授权业务营收85百万瑞典克朗，同比增长44%，客户结构多元，无大额单一客户贡献，且2026年授权收入损失预计低于此前60-90百万瑞典克朗的预估区间。 3. 业务板块表现：教育产品增长19%（本地货币24%），超声业务增长34%，工业板块增长24%（本地货币27%），研发业务平稳推进，医疗设备板块稳步成长。 4. 区域表现：美国市场Q2同比增长、季环比强劲；EMEA增长60%，东欧贡献主要增量；中国市场因本土制造政策存在结构性逆风，公司正通过增投销售团队、产品创新等措施应对。 5. 战略与运营进展：特拉维夫新生产基地于2026年Q2末投用，提高产能与成本效率；香港亚太服务中心开业，加强区域服务布局；公司无债务，期末现金达658百万瑞典克朗，财务状况稳健。二、风险与关注 1. 授权、研发收入波动性较大，季度间波动明显；教育业务依赖大额订单，订单交付时间节点影响季度业绩。 2. 汇率波动带来业绩压力，美元兑以色列谢克尔汇率变动曾产生约6百万瑞典克朗的汇兑损失。 3. 中国市场受本土制造政策限制，业务拓展面临挑战；机器人行业新进入者虽长期利好市场，但短期对公司收入暂无显著影响。 三、投资线索 1. 机器人手术行业快速发展，新平台推出推动培训与模拟需求增长，公司作为核心供应商受益；Intuitive等客户数字服务续约率100%，体现产品粘性。 2. 超声结构创新与市场渗透加速，公司相关软件模块与整合持续推进，长期增长潜力明确。 3. 计划每年调整产品价格，价格上涨效应逐步释放；将通过并购加强各细分领域布局，现金储备充足支撑潜在动作。 二、音频原文（转写） in the construction in our new production facilities in Tel Aviv. For the first half year, we have invested 12 million and in total, approximately 17. And as we talked about, these new facilities were commissioned at the end of the second quarter. nothing to mention around financing activities. So at June 30, our cash position was 658million. Back to you, Tom. Thank you, Anna. Soto wrap up, quarter two was a strong quarter forCervico Science. We had strong growth of revenu es. Adjusted EBIT reached 15 margin, which is inline with our profitability for yet, and now license revenues were up 44% year over year. All of this demonstrates that the actions that we'vetaken to improve profitability in the customer offering are delivering results. We have momentumnow in educational products across all regions.We have a growing and increasingly diverse robotics ecosystem. with multiple platform companiesentering the market at scale Our ultrasound business is growing and accelerating. And we open up. Our Apex Service Hub and our new Tel Aviv production facility during this quarter. And our strategy is delivering both financial and operational results. The opportunity in front of cervical science is significant. Simulation will becomea central port. for how healthcare trains itself. professionals. And we in turn. to lead that.sheep. Finally, I want to take the opportunity to thank the entire CIRCA Science team For theirfantastic work and for their continuous strength. commitment. And with that. I would like to open up the floor for questions. If you wish to aska question, please dial pound key five on yourtelephone keypad to enter the queue. If you wishto withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christian Lee from Pareto Securities. Please go ahead. Thank you. Good morning, Tomand Anna. My two questions are basically related to the license revenues. So the first one is if you could give us some color on the composition of license revenue in the second quarter. If you had any larger package deals contributing orwas it more broad based across customers and would it be possible to quantify or give us some indication? of how much of the revenues were driven by my intuitive subscription renewals as much as possible. So I can answer that. So first, there was no -- we don't comment on specific customers as youknow, but we had a healthy mix of revenues fromdifferent 看 In the. quarter So it was not like.if you take inclusive aside So there was not like one major. license deed or package deed. Andthen the second question is related to the renewals, it's a relatively small volume of renewersstill. intuitive was clear about that in their earnings call and they did not The renewal did not have a significant effect on the total. license revenues is quarter. But it's of course a positive news. Thank you. Okay. My second question is Now that you have indicated that in future related revenue loss will be. below the. Show the system. 29 million has not the This means that you are in a better position to hit your 2027 adjusted EBIT margin target of at least. fifteen percent already, this. Here. and could you also more broadly give some UM HECK given the increasingly positive robotics outlook Do you think The more than fifteen percent is. じゃ、ちょっと倒して。 that's a long-term target. 哼。So obviously, sincewe have communicated that the profitability for2026 will be lower than our financial targets,this is of course the fact that we now have ourfinancial targets in terms of profitability. Itmeans that we are ahead of the plan that we haveset. So yes, that's a good -- that's a strong positive development, right? However, it's a bit too early. to to say how theentire year would pay out. And also whether thetargets are set too conservatively, I think that it's 诶 we need to deliver at these levels notjust 1 or 2 quarters, but consistently across quarters in order to be able to raise the ambition. But we have been clear also in the capital markets day that when we feel that we Or we are the. situation where we meet the financial targets,then of course we'll revised the